Avacta Group PLC - Asset Resilience Ratio
Avacta Group PLC (AVCT) has an Asset Resilience Ratio of 8.33% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Avacta Group PLC's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2020)
This chart shows how Avacta Group PLC's Asset Resilience Ratio has changed over time. See Avacta Group PLC balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Avacta Group PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Avacta Group PLC (AVCT) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX5.02 Million | 8.33% |
| Total Liquid Assets | GBX5.02 Million | 8.33% |
Asset Resilience Insights
- Limited Liquidity: Avacta Group PLC maintains only 8.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Avacta Group PLC Industry Peers by Asset Resilience Ratio
Compare Avacta Group PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Avacta Group PLC (2016–2020)
The table below shows the annual Asset Resilience Ratio data for Avacta Group PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 29.67% | GBX20.02 Million ≈ $2.44K |
GBX67.46 Million ≈ $8.21K |
+16.99pp |
| 2017-07-31 | 12.68% | GBX4.00 Million ≈ $486.68 |
GBX31.55 Million ≈ $3.84K |
-13.95pp |
| 2016-07-31 | 26.63% | GBX10.00 Million ≈ $1.22K |
GBX37.55 Million ≈ $4.57K |
-- |
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more